Aging and Alzheimer's disease pathology
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
The number of people with dementia worldwide is predicted to increase to 131.5 million by 2050. When studying dementia, understanding the basis of the neuropathological background is very important. Taking Alzheimer's disease (AD) neuropathology as an example, we know that the accumulation of abnormal structures such as senile plaques and neurofibrillary tangles is a hallmark. Macroscopic atrophy affects the entorhinal area and hippocampus, amygdala, and associative regions of the neocortex. Braak advocates the spread of tau deposits from the entorhinal to associative regions of the neocortex as the disease progresses. If the AD has only tau pathology, the degree and distribution of tau deposition may be associated with clinical symptoms. However, AD is also accompanied by amyloid‐β deposition and even atrophy. Although it is possible to make a neuropathological diagnosis of AD from the spread of amyloid and tau depositions, neuropathological abnormal protein accumulation cannot explain all clinical symptoms of AD. There is an ambiguity between clinical symptoms and neuropathological findings. It is important to understand neuropathological findings while understanding that this ambiguity exists. So, for the reader's help, first we briefly explain the changes in the brain with age, and then describe AD as a typical disease of dementia; finally we will describe the diseases that mimic AD for neurologists who are not experts in neuropathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Staging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
The distribution of tau in the mammalian central nervous system.
Binder, L. I., Frankfurter, A., & Rebhun, L. I. (1985) · The Journal of cell biology · doi:10.1083/jcb.101.4.1371 · Cited by 1,588
Uber eine eigenartige Erkrankung der Hirnrinde
Alzheimer, A. (1907) · Medical Entomology and Zoology · Cited by 1,503
Primary age-related tauopathy (PART): a common pathology associated with human aging
Crary, J. F., Trojanowski, J. Q., Schneider, J. A., Abisambra, J. F., Abner, E. L., Alafuzoff, I., Arnold, S. E., Attems, J., Beach, T. G., Bigio, E. H., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1349-0 · Cited by 1,467 · cited 1×
“Neuropathological criteria for PART have been proposed to further subdivide PART cases into “definite” (Braak stage ≤ IV, ThalAβ phase 0) and “possible” (Braak stage ≤ IV, Thal Aβ phase 1–2).(48) NFTs begin to appear in the first decade of life, increase with aging, and are present in 100% of people in their 40s.”
BackgroundDekaban, A. S., & Sadowsky, D. (1978) · Annals of Neurology · doi:10.1002/ana.410040410 · Cited by 1,014
Mutation-Specific Functional Impairments in Distinct Tau Isoforms of Hereditary FTDP-17
Hong, M. (1998) · Science · doi:10.1126/science.282.5395.1914 · Cited by 1,003
The Pathogenesis of Senile Plaques
DICKSON, D. W. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199704000-00001 · Cited by 753
The Prevalence and Malignancy of Alzheimer Disease: A Major Killer
Katzman, R. (1976) · Archives of Neurology · doi:10.1001/archneur.1976.00500040001001 · Cited by 619
Neuropathologic Features of Amnestic Mild Cognitive Impairment
Petersen, R. C., Parisi, J. E., Dickson, D. W., Johnson, K. A., Knopman, D. S., Boeve, B. F., Jicha, G. A., Ivnik, R. J., Smith, G. E., Tangalos, E. G., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.665 · Cited by 616
Phosphorylated Tau Protein Is Integrated into Paired Helical Filaments in Alzheimer's Disease1
IHARA, Y., NUKINA, N., MIURA, R., & OGAWARA, M. (1986) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a135662 · Cited by 532
Prevalence and Malignancy of Alzheimer Disease
Lijtmaer, H., Fuld, P. A., & Katzman, R. (1976) · Archives of Neurology · doi:10.1001/archneur.1976.00500040088017 · Cited by 517
The discovery of Alzheimer's disease
Hippius, H., & Neundörfer, G. (2003) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2003.5.1/hhippius · Cited by 516
Alafuzoff, I., Arzberger, T., Al‐Sarraj, S., Bodi, I., Bogdanovic, N., Braak, H., Bugiani, O., Del‐Tredici, K., Ferrer, I., Gelpi, E., et al. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00147.x · Cited by 467 · cited 8×
“Staging following immunohistochemical staining is widely used as a neuropathological criterion for AD.(27) On the other hand, Thal phases(28) are used to classify the deposition of Aβ plaques.”
MethodInfluentialStaging of Argyrophilic Grains: An Age-Associated Tauopathy
Saito, Y., Ruberu, N. N., Sawabe, M., Arai, T., Tanaka, N., Kakuta, Y., Yamanouchi, H., & Murayama, S. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.9.911 · Cited by 431
Hirano, A., Dembitzer, H. M., Kurland, L. T., & Zimmerman, H. M. (1968) · PubMed · Cited by 300
BRAAK, H., & BRAAK, E. (1989) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1989.tb01146.x · Cited by 279
Argyrophilic Grain Disease Is a Sporadic 4-Repeat Tauopathy
Togo, T., Sahara, N., Yen, S.-H., Cookson, N., Ishizawa, T., Hutton, M., de Silva, R., Lees, A., & Dickson, D. W. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.6.547 · Cited by 273
THE FINE STRUCTURE OF SOME INTRAGANGLIONIC ALTERATIONS
HIRANO, A., DEMBITZER, H. M., KURLAND, L. T., & ZIMMERMAN, H. M. (1968) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-196804000-00001 · Cited by 245
Braak, H., & Braak, E. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90204-7 · Cited by 236
Diffuse type of senile plaques in the brains of Alzheimer-type dementia
Yamaguchi, H., Hirai, S., Morimatsu, M., Shoji, M., & Harigaya, Y. (1988) · Acta Neuropathologica · doi:10.1007/bf00687420 · Cited by 235
Hirano bodies and related neuronal inclusions
Hirano, A. (1994) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1994.tb00951.x · Cited by 186
Tau gene mutations: dissecting the pathogenesis of FTDP-17
Ingram, E. M., & Spillantini, M. G. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02440-1 · Cited by 177
Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease
Jellinger, K. A., & Attems, J. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0156-7 · Cited by 167
Hirano Body Filaments Contain Actin and Actin-Associated Proteins
Galloway, P. G., Perry, G. L., & Gambetti, P. L. (1987) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-198703000-00006 · Cited by 140
Thal, D. R., Tredici, K. D., Ludolph, A. C., Hoozemans, J. J. M., Rozemüller, A. J. M., Braak, H., & Knippschild, U. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0871-6 · Cited by 134
Bancher, C., & Jellinger, K. A. (1994) · Acta Neuropathologica · doi:10.1007/bf00296494 · Cited by 118
Prevalence and Disease Associations of Argyrophilic Grains of Braak
Martínez‐Lage, P., & Muñoz, D. G. (1997) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199702000-00006 · Cited by 106
Yamada, M. (2003) · Neuropathology · doi:10.1046/j.1440-1789.2003.00522.x · Cited by 100
Neuropathology of mild cognitive impairment
Saito, Y., & Murayama, S. (2007) · Neuropathology · doi:10.1111/j.1440-1789.2007.00806.x · Cited by 92 · cited 1×
“On the other hand, when patients visit a neurology or memory clinic, they tend to present with mild cognitive impairment-like or AD-like clinical features.(32,33) These are largely related to the bias of the department that the patient visited.”
BackgroundGranulovacuolar degeneration: a neurodegenerative change that accompanies tau pathology
Köhler, C. N. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1562-0 · Cited by 91
Current concepts of neuropathological diagnostics in practice: neurodegenerative diseases
Kovacs, G. G., & Budka, H. (2010) · Clinical Neuropathology · doi:10.5414/npp29271 · Cited by 85
Rami, L., Sala‐Llonch, R., Solé‐Padullés, C., Fortea, J., Olives, J., Lladó, A., Peña-Gómez, C., Balasa, M., Bosch, B., Antonell, A., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120223 · Cited by 80
Alzheimer’s disease in the 100 years since Alzheimer’s death
Ryan, N. S., Rossor, M. N., & Fox, N. C. (2015) · Brain · doi:10.1093/brain/awv316 · Cited by 69
Clinical aspects of argyrophilic grain disease.
Ikeda, K., Akiyama, H., Arai, T., Matsushita, M., Tsuchiya, K., & Miyazaki, H. (2000) · PubMed · Cited by 62
Xu, M., Shibayama, H., Kobayashi, H., Yamada, K., Ishihara, R., Zhao, P., Takeuchi, T., Yoshida, K., Inagaki, T., & Nokura, K. (1992) · Acta Neuropathologica · doi:10.1007/bf00304627 · Cited by 60
Neuropathological Asymmetry in Argyrophilic Grain Disease
Adachi, T., Saito, Y., Hatsuta, H., Funabe, S., Tokumaru, A. M., Ishii, K., Arai, T., Sawabe, M., Kanemaru, K., Miyashita, A., et al. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181e5ae5c · Cited by 60
Togo, T. (2005) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.13.12.1083 · Cited by 55
Togo, T., Isojima, D., Akatsu, H., Suzuki, K., Uchikado, H., Katsuse, O., Iseki, E., Kosaka, K., & Hirayasu, Y. (2005) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200512000-00008 · Cited by 51
Tolnay, M., Mistl, C., Ipsen, S., & Probst, A. (1998) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.1998.00090.x · Cited by 47
Yamada, M., Itoh, Y., Otomo, E., Suematsu, N., & Matsushita, M. (1996) · Neuropathology · doi:10.1111/j.1440-1789.1996.tb00162.x · Cited by 47
Argyrophilic Grains Are Reliable Disease-Specific Features of Corticobasal Degeneration
Tatsumi, S., Mimuro, M., Iwasaki, Y., Takahashi, R., Kakita, A., Takahashi, H., & Yoshida, M. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000022 · Cited by 40
Neuropathological comorbidity associated with argyrophilic grain disease
Yokota, O., Miki, T., Ikeda, C., Nagao, S., Takenoshita, S., Ishizu, H., Haraguchi, T., Kuroda, S., Terada, S., & Yamada, N. (2018) · Neuropathology · doi:10.1111/neup.12429 · Cited by 38
France Will No More Reimburse Available Symptomatic Drugs Against Alzheimer’s Disease
Krolak‐Salmon, P., Dubois, B., Sellal, F., Delabrousse-Mayoux, J.-P., Vandel, P., Amieva, H., Jeandel, C., Andrieu, S., & Perret‐Liaudet, A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180843 · Cited by 20
Nakano, H., Kobayashi, K., Sugimori, K., Shimazaki, M., Miyazu, K., Hayashi, M., & Furuta, H. (2004) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000076344 · Cited by 19
Hirano body‐rich subtypes of Creutzfeldt–Jakob disease
Martínez-Sáez, E. A., Gelpí, E., Rey, M. J., Ferrer, I., Ribalta, T., Botta‐Orfila, T., Nos, C., Yagüe, J., & Sánchez‐Valle, R. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2011.01208.x · Cited by 11
Cited by
Dhapola, R., Hota, S. S., Sarma, P., Bhattacharyya, A., Medhi, B., & Reddy, D. H. (2021) · Inflammopharmacology · doi:10.1007/s10787-021-00889-6 · Cited by 383
Więckowska-Gacek, A., Mietelska-Porowska, A., Wydrych, M., & Wojda, U. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101397 · Cited by 343
“Globally, about 47 million people were living with dementia in 2015 and this number is projected to reach 152 million by 2050 (Sengoku, 2020; World Health Organization, 2020).”
Alzheimer’s Disease: An Updated Overview of Its Genetics
Andrade-Guerrero, J., Santiago-Balmaseda, A., Jeronimo-Aguilar, P., Vargas-Rodríguez, I., Cadena-Suárez, A. R., Sánchez-Garibay, C., Pozo-Molina, G., Méndez-Catalá, C. F., Cardenas-Aguayo, M.-D.-C., Diaz-Cintra, S., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043754 · Cited by 336
Role of Chemokines in the Development and Progression of Alzheimer’s Disease
Wojcieszak, J., Kuczyńska, K., & Zawilska, J. B. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-022-02047-1 · Cited by 97
“…changes in AD encompass formation and accumulation of pathological structures in the brain, namely extracellular senile plaques containing aggregates of amyloid β peptide (Aβ) and intracellular neurofibrillary tangles consisting of hyperphosphorylated tau protein (Saido 2013; Sengoku 2020).”
BackgroundBrain modulation by the gut microbiota: From disease to therapy
Mitra, S., Dash, R., Nishan, A. A., Habiba, S. U., & Moon, I. S. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2022.12.001 · Cited by 91
Metadata
- Authors
- Sengoku, R.
- Venue
- Neuropathology
- Publisher
- Wiley
- Published
- 2019-12-21
- Volume
- 40
- Issue
- 1
- Pages
- 22-29
- ISSN
- 0919-6544 (ISSN-L)
- 1440-1789
- OpenAlex
- W2995252331
- Cited by
- 288
- References
- 50
- FWCI
- 16.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.